uniQure N.V..
QURE.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
uniQure N.V. is a gene therapy company focused on developing and commercializing transformative genetic therapies for patients with severe unmet medical needs. The company's pipeline includes gene therapy programs for hemophilia B, Huntington's disease, and other liver-directed and CNS (central nerv...Show More
Better Health for All
10
uniQure's core business is developing gene therapies for severe unmet medical needs, with 100% of its portfolio focused on revolutionary health benefits. Its lead product, Hemgenix for hemophilia B, has demonstrated transformative health benefits, reducing mean yearly bleeding rates by 54% and allowing 94% of patients to stop prophylaxis, with sustained Factor IX activity for four years.
1
The company has no revenue from harmful products.
2
uniQure has invested over a decade in research and clinical development for Hemgenix, conducting three clinical trials across 34 global sites involving 67 adults, and is also conducting a Phase I/II clinical trial for AMT-130 for Huntington's Disease.
3
However, Hemgenix is priced at $3.5 million per dose, significantly exceeding ICER's suggested price of $2.9 million, making it one of the most expensive drugs globally.
4
The company's licensing agreement with CSL Behring includes royalty and milestone payments, but no evidence of patent flexibility or access programs for lower-income countries is provided.
5
uniQure provides information on potential risks and side effects for its therapies, including unknown long-term effects and the permanent nature of treatment.
6
Clinical trials for AMT-130 follow ethical guidelines, including informed consent and an independent study monitoring board.
7
While Hemgenix aims to prevent bleeding episodes, the company's primary focus is on treatment rather than broader preventative health measures.
Fair Money & Economic Opportunity
0
The provided articles do not contain any information relevant to QURE.US's activities concerning 'Fair Money & Economic Opportunity'.
1
The articles explicitly state that no data related to financial services, lending practices, or economic opportunity initiatives is present.
2
Therefore, no KPIs under this value can be scored based on the evidence provided.
Fair Pay & Worker Respect
0
No evidence available to assess uniQure N.V. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points regarding fair trade and ethical sourcing practices, such as fair-trade certification share, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend, were found in the provided articles.
1
Honest & Fair Business
-40
The company has procedures for receiving and handling complaints regarding accounting, internal controls, auditing, and code of conduct violations, including confidential and anonymous submissions.
1
The Audit Committee monitors compliance with the Foreign Corrupt Practices Act and the company’s policies on ethical business practices.
2
Kind to Animals
0
No evidence available to assess uniQure N.V. on Kind to Animals.
No War, No Weapons
0
No evidence available to assess uniQure N.V. on No War, No Weapons.
Planet-Friendly Business
0
No relevant data was found in the provided articles to assess QURE.US against the Planet-Friendly Business ethical value. indicated a 404 error, and contained no information pertaining to the company's environmental performance.
1
Respect for Cultures & Communities
0
No evidence available to assess uniQure N.V. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The provided articles do not contain specific, concrete data points for any of the KPIs related to Safe & Smart Tech. Information regarding data breach severity, AI ethics governance, cybersecurity investment, privacy certifications, security training effectiveness, encryption implementation, AI audit practices, algorithmic transparency, unauthorized data use, user data control, authentication security, vulnerability management, bug bounty effectiveness, privacy by design, security testing coverage, data minimization, regulatory compliance, algorithmic harm remediation, or digital rights advocacy is not available in the given evidence.
1
Zero Waste & Sustainable Products
-30
In 2023, uniQure N.V. recycled 82% of its laboratory waste.
1
The company has implemented five waste reduction initiatives, including an established hazardous waste program with annual training, a waste neutralization system for liquid waste, a partnership with a waste management vendor, a single-stream processor for waste separation, and municipal solid waste processing to separate recyclables and compostable material.
2
The company has an established hazardous waste program with annual training on proper handling and disposal, and uses an authorized waste removal company for hazardous and biological waste.
3
There have been no waste disposal violations reported in the past three years.
4
UniQure has company-wide waste reduction targets with timelines and a commitment to proactive sustainability measures for facility engagement in 2024.
5